G lycine is the smallest and simplest possible amino acid (Fig. 1a, center) and one of the building blocks of proteins. It is synthesized and degraded in our body as part of the ubiquitous serine cycle. Since its discovery in 1820 by Henri Braconnot, it has taken more than a century to understand its prominent roles as a neurotransmitter and a receptor co-agonist in the central nervous system. The extracellular dynamics of glycine have since attracted great interest across fields of biomedical research, yet its understanding has been limited by the relatively crude monitoring tools. Now, Zhang et al. 1 have developed a FRET-based glycine reporter enabling dynamic mapping of glycine concentration in brain tissue with submicron resolution.
The inhibitory neurotransmitter function of glycine is particularly important in the retina, the brainstem, and the spinal cord. In this role it acts by activating the ionotropic glycine receptor, prompting chloride entry, which hyperpolarizes the neuronal membrane (Fig. 1a, left) . In its second role, which occurs across brain regions, glycine acts an ambient co-agonist of ionotropic NMDA receptors (NMDARs) activated by the common excitatory neurotransmitter glutamate (Fig. 1a, right) . Because activation of NMDARs requires coincident presynaptic glutamate release and postsynaptic cell depolarization (which relieves their Mg 2+ block), they are considered essential to the synaptic mechanism of Hebbian plasticity underpinning memory formation in the brain 2 . For these receptors to function, the binding of either of the two endogenous co-agonists, glycine or d-serine, is required. Thus, the extracellular level of glycine (as well as d-serine) could critically control NMDAR availability and hence the efficacy of plasticity induction in neural circuits 3, 4 . Consequently, monitoring glycine concentration should provide important clues about the ability of and as a co-agonist for the NMDA receptor operating a Na + /Ca 2+ channel (right); the latter is activated by the main neurotransmitter glutamate upon removal of the magnesium block. b, The Agrobacterium tumefaciens protein Atu2422 binds glycine (Gly), l-serine (Ser), and GABA (i). Aiming to establish binding specificity for glycine, the protein is first mutated at F77A/A100Y to prevent GABA binding (ii). Second, it is mutated at F77A/L202 to suppress l-serine binding, which exposes a binding site for glutamate (Glu, iii). To block the latter, the A100Y mutation is restored to generate the molecule (AYW) providing glycine binding specificity (iv). c, The FRET sensor is designed by cloning the AYW molecule between the established FRET pair Venus-ECFP. FRET interaction provides relatively strong Venus emission in the absence of glycine binding (left) that weakens upon glycine binding (hence conformational change in AYW), which thus reduces the Venus/ECFP emission ratio (right). d, Diagram depicting a dendritic fragment (shaft and spine), presynaptic bouton (axon), and the surrounding astroglial fragments. Extracellular GlyFS FRET readout in acute hippocampal slices reveals higher extracellular concentrations of glycine near dendritic shafts compared to spines (left). Afferent stimulation increases extracellular glycine concentration (right), which might affect the relative roles of the two endogenous NMDAR co-agonists, glycine and d-serine.
local excitatory connections to undergo memory-forming changes.
The core design of biosensors for glycine and other neurotransmitters has long involved micro-electrodes employing electrochemical properties of selected materials 5 . However, electrode-based methods can only provide macroscopic readout from one or a few sites in the tissue and are prone to signal contamination from local cell damage. The ongoing revolution in molecular optical imaging is paving the way for noninvasive, high-resolution dynamic mapping of signaling molecules in the brain 6, 7 . Taking advantage of this trend, the authors 1 set out to develop an optical sensor for glycine using a computer-assisted molecular design combined with targeted protein mutations. They elected to use the ratiometric FRET signal as a readout because it is insensitive to fluctuations in sensor concentration, excitation power, or photobleaching. Thus, the strategy was to obtain a specific glycine-binding protein and to connect it to a FRET pair so that the glycine-induced conformational change alters the fluorescent FRET signal.
To achieve this, the authors started with the bacterial protein Atu2422 (from Agrobacterium tumefaciens), which is known to change its conformation upon the binding of glycine, l-serine, or GABA (Fig. 1b, i) . The task was to redesign its binding site to diminish its affinity for l-serine and GABA. Based on analyses of the 3D molecular structure, the authors first produced a F77A/A100Y (AY) mutant showing no detectable GABA binding (Fig. 1b, ii) and then a F77A/L202W (AW) mutant showing neither GABA nor l-serine binding (Fig. 1b, iii) . However, the latter mutant had significant affinity to glutamate, prompting the authors to restore the A100Y mutation (Fig. 1b, iv) . Thus, by consistently referring their mutation strategy to a computer-assisted molecular design, the authors obtained a protein (AYW) showing specific glycine binding.
Next, the AYW protein was cloned between the well-established FRET pair, ECFP and Venus, using flexible amino acid-chain linkers (Fig. 1c, left) . This design was further adjusted by truncating and modifying the linkers to maximize the FRET response to glycine binding. The resulting glycine FRET sensor, termed GlyFS, had a ~25% fluorescence dynamic range (Fig. 1c, right) .
To deliver the GlyFS sensor to the brain extracellular space, the authors microinjected a GlyFS-streptavidin mixture into the surface-biotinylated tissue of acute hippocampal slices. At this stage, they were using two-photon excitation microscopy combined with patch-clamp electrophysiology to map, with submicron resolution, GlyFS signal near visualized dendrites of principal neurons (dialyzed with a chromatically distinct morphological tracer). In these settings, two physiologically significant observations were made. First, glycine tends to accumulate near dendritic shafts rather than at the spines hosting excitatory synapses enriched in NMDARs (Fig. 1d, left) . This observation lends further support to the hypothesis that glycine, rather than d-serine, is the main co-agonist of extrasynaptic NMDARs 4 . Second, the authors have found that excitatory neuronal activity, either high or low frequency, boosts extracellular glycine levels (Fig. 1d, right) .
Such observations open a new horizon for our ability to monitor glycine dynamics in the nervous tissue while prompting multiple questions about its physiological implications and the underlying cellular mechanisms. In addition to mapping out and exploring inhibitory activity in the spinal cord and brainstem, some important and intriguing quests here concern the contributing roles of neurons and astrocytes in regulating extracellular glycine and how this affects NMDARdependent memory trace formation across central circuits. In the latter context, developing an optical sensor for the other endogenous NMDAR co-agonist, d-serine, should be high on the priority list, to help understand how the two co-agonists interact in providing an 'optimal' availability of NMDARs in the brain. 
